University of Pecs

pte.hu

Total trials

97

Active

18

Phase 3

7

Total enrollment

30,352

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 4 of 4 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Oral iron supplementation1
Intravenous iron supplementation1
alverine-citrate + simethicone and lactase1
alverin-citrate + simethicone with placebo1

Next readouts

  • 2026-09
  • 2027-12-31

Top conditions

  • COVID-195
  • Sepsis4
  • Physical Inactivity4
  • Knee Osteoarthritis4
  • Diabetes Mellitus3
  • Diabetes Mellitus, Type 23
  • Urinary Incontinence3
  • Cardiac Arrest (CA)3

Frequently asked questions about University of Pecs

How many clinical trials does University of Pecs have on ClinicalTrials.gov?
University of Pecs is listed as the lead sponsor on 97 clinical trials in ClinicalTrials.gov, 18 of which are currently active (recruiting, enrolling, or ongoing).
How many of University of Pecs's trials are in Phase 3?
7 of University of Pecs's trials are in Phase 3, spread across 4 active drug programs.
What therapeutic areas does University of Pecs focus on?
University of Pecs's most-studied conditions on ClinicalTrials.gov are COVID-19, Sepsis, Physical Inactivity, Knee Osteoarthritis, Diabetes Mellitus.
When are University of Pecs's next clinical trial readouts?
University of Pecs has 2 upcoming primary-completion readouts tracked here; the soonest is “The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION)”, expected around 2026-09.